Table 1.

Pre-clinical and clinical antioxidant therapies in FRDA.

Compound	Pre-Clinical Studies in FRDA			Clinical Trials in FRDA
	Model	Doses/Treatment	Ref.	Nº Subjects	Doses/Treatment	Ref.
Resveratrol	YG8R mouse	200 mg/kg daily for 3 days. Subcutaneous injection.	[170]	27 FRDA patients: 13 low dosis and 14 high dosis	0.5 g or 2.5 g twice daily for 12 weeks. Capsules.	[171]
	Human fibroblast MSCiPSC-derived neurons	25 µM to 125 µM once 25 µM to 125 µM once 10 µM to 50 µM once	[172]	40 patients (estimated)	2 g daily for 24 weeks. Capsules.	ClinicalTrials.gov Id: NCT03933163
Sulforaphane (SFN)	Mouse NSC34 motor neurons Human fibroblasts	5 µM for 24 h 10 µM for 24 h	[180]
	Neural stem cells KIKO mouse	5 µM for 2, 6, and 24 h	[181]
	Human fibroblast	10 µM for 2, 6, and 24 h	[182]
Omaveloxolone	Cerebellar Granule Neurons KIKO and YG8R mice Human Fibroblast	50 nM for 24 h 50 nM for 24 h	[183]	103 patients	150 mg daily for 48 weeks. Capsules.	[184]
Melatonin				Case report: 1 FRDA patient	5 mg and 10 mg	[188]